However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.<h4>Methods</h4>We used dual-recombinase genetically engineered mouse models of Kras+/G12V;Trp53-/- lung cancer to evaluate the effects of Raf1 ablation alone or in combination with Araf, Egfr, or Ddr1. The gene discussed is TP53; the disease is lung cancer.